Amgen (AMGN) Common Equity (2009 - 2026)

Amgen (AMGN) has reported Common Equity for 18 consecutive years, with $9.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 48.06% year-over-year to $9.2 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 48.06% YoY), while the FY2025 annual figure was $8.7 billion, up 47.32% from the prior year.
• Common Equity came in at $9.2 billion for Q1 2026 at Amgen, up from $8.7 billion in the prior quarter.
• The five-year high for Common Equity was $9.6 billion in Q3 2025, with the low at $916.0 million in Q1 2022.
• Average Common Equity over 5 years is $6.0 billion, with a median of $6.2 billion recorded in 2025.
• Across the five-year window, Common Equity tumbled 90.19% in 2022 and soared 483.84% in 2023, its largest moves.
• Year by year, Common Equity stood at $3.7 billion in 2022, then soared by 70.23% to $6.2 billion in 2023, then declined by 5.7% to $5.9 billion in 2024, then soared by 47.32% to $8.7 billion in 2025, then grew by 6.14% to $9.2 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $9.2 billion, $8.7 billion, and $9.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.